Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
In this section, we usually try to help investors determine whether Sona Nanotech is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sona Nanotech has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
It is not possible to calculate the future cash flow value for
Sona Nanotech. This is due to cash flow or dividend data being
unavailable. The share price is
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Sona Nanotech's earnings available for a low price, and how does
this compare to other companies in the same industry?
Sona Nanotech has negative assets, we can't compare the value of its assets to the CA Medical Equipment industry average.
Take a look at our analysis of SONA’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through Sona Nanotech's regulatory filings and announcements.
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Sona Nanotech has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.
Show me the analysis anyway
The future performance of a company is measured in the same way as past
performance, by looking at estimated
and how much profit it is expected to make.
Future estimates come from
professional analysts. Just like forecasting the weather, they don’t always get
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
expected to grow at an
Unable to compare Sona Nanotech's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
Unable to compare Sona Nanotech's earnings growth to the Canada market average as no estimate data is available.
Unable to compare Sona Nanotech's revenue growth to the Canada market average as no estimate data is available.
Unable to determine if Sona Nanotech is high growth as no earnings estimate data is available.
Unable to determine if Sona Nanotech is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Sona Nanotech's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Mr. Darren Rowles has been President and Chief Executive Officer at Sona Nanotech Limited since October 2017. Mr. Rowles has almost 15 years of experience in the diagnostic and nanoparticle industry and previously worked for one of the leading providers of technologies to the global diagnostics market, where he specialised in product manufacture and development in the area of noble metal nanoparticles and lateral flow diagnostics. Mr. Rowles is a key opinion leader at industry seminars and conferences and acts as an advisory board member to the World Gold Council. Mr. Rowles holds a BSC in Biomedical Science and Toxicology from the University of Wales Institute Cardiff (2003) and a Master of Business Administration from the University of Bath (2017).
Insufficient data for Darren to compare compensation growth.
Darren's remuneration is about average for companies of similar size in Canada.
Management Team Tenure
Average tenure of the
management team in years:
The tenure for the Sona Nanotech management team is about average.
President & CEO
CFO & Corporate Secretary
CTO & Founder
Director of R&D & Production and Founder
Product Science Advisor & Founder
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Sona Nanotech board of directors is about average.
Board of Directors
Chairman of the Board
Member of Advisory Board
Member of Advisory Board
Who owns this company?
Recent Insider Trading
More shares have been bought than sold by Sona Nanotech individual insiders in the past 3 months, but not in substantial volumes.
Do Insiders Own Lots Of Shares In Sona Nanotech Inc. (CNSX:SONA)?
Check out our latest analysis for Sona Nanotech CNSX:SONA Ownership Summary, September 3rd 2019 What Does The Institutional Ownership Tell Us About Sona Nanotech? … We can see that Sona Nanotech does have institutional investors; and they hold 8.9% of the stock. … General Public Ownership The general public -- mostly retail investors -- own 73% of Sona Nanotech.
We Think Sona Nanotech (CNSX:SONA) Has Us A Very Heavy Debt Load
CNSX:SONA Historical Debt, July 11th 2019 How Strong Is Sona Nanotech's Balance Sheet? … Zooming in on the latest balance sheet data, we can see that Sona Nanotech had liabilities of CA$2.28m due within 12 months and liabilities of CA$700.9k due beyond that. … Because it carries more debt than cash, we think it's worth watching Sona Nanotech's balance sheet over time.
Sona Nanotech Inc. manufactures gold nanorod products for diagnostic test products and medical treatment applications. Its products portfolio comprises Gemini 650NM, Gemini 700NM, Gemini 750NM, Gemini 800NM, Gemini 850NM, Gemini 900NM, Gemini 950NM, and Gemini 1050NM, as well as Gemini nanorods kit. The company has collaborations with Soma Bioscience Ltd. to produce diagnostic tests; Anteo Diagnostics Limited to develop products that improve the development and performance of lateral flow immunoassays; and University of Birmingham to develop nanorods for tissue imaging. Sona Nanotech Inc. is based in Halifax, Canada.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.